| Title |
Long-Term Proton Pump Inhibitor Use is Associated with Vascular Calcification in Chronic Kidney Disease: A Cross-Sectional Study Using Propensity Score Analysis
|
|---|---|
| Published in |
Drug Safety, May 2013
|
| DOI | 10.1007/s40264-013-0062-6 |
| Pubmed ID | |
| Authors |
Maria Fusaro, Marianna Noale, Giovanni Tripepi, Sandro Giannini, Angela D’Angelo, Angelo Pica, Lorenzo A. Calò, Davide Miozzo, Maurizio Gallieni |
| Abstract |
Proton pump inhibitors (PPIs) are a class of drugs that is extensively used for common gastrointestinal disorders and often prescribed long-term for years. Long-term PPI treatment is associated with an increased risk of fractures in the general population. Several studies have suggested a relationship between vascular calcification, which is a predictor of cardiovascular morbidity and mortality, impaired bone metabolism and fractures. In dialysis patients, vascular calcifications are widespread and are connected to bone health. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 29% |
| United Kingdom | 1 | 14% |
| Unknown | 4 | 57% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 71% |
| Practitioners (doctors, other healthcare professionals) | 2 | 29% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Japan | 1 | 2% |
| Unknown | 41 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 21% |
| Student > Bachelor | 5 | 12% |
| Student > Master | 5 | 12% |
| Student > Doctoral Student | 4 | 9% |
| Student > Ph. D. Student | 3 | 7% |
| Other | 5 | 12% |
| Unknown | 12 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 47% |
| Nursing and Health Professions | 3 | 7% |
| Agricultural and Biological Sciences | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Other | 2 | 5% |
| Unknown | 14 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2013.
All research outputs
#7,971,757
of 25,403,829 outputs
Outputs from Drug Safety
#869
of 1,852 outputs
Outputs of similar age
#64,728
of 206,019 outputs
Outputs of similar age from Drug Safety
#12
of 30 outputs
Altmetric has tracked 25,403,829 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 1,852 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,019 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.